FDAnews
www.fdanews.com/articles/142743-fda-official-agency-may-need-accelerated-withdrawal-process

FDA Official: Agency May Need Accelerated Withdrawal Process

December 27, 2011
The FDA should consider a speedier way to withdraw indications granted under accelerated approval in light of the recent resource-intensive, time-consuming effort to revoke the metastatic breast cancer (MBC) indication for Genentech’s Avastin, CBER Director Karen Midthun says.
Washington Drug Letter